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Aim: To compare the effectiveness of photodynamic therapy (PDT) and PDT combined with intravitreal triamcinolone (IVTA) and
vascular endothelial growth factor inhibition (anti-VEGF) in age-related macular degeneration (AMD).
Materials and methods: Eighty eyes of 80 patients diagnosed with choroidal neovascularization (CNV) caused by AMD were included
in the study. PDT was carried out on 40 eyes in group I, and PDT combined with 4 mg IVTA and anti-VEGF (1.25 mg bevacizumab in
20 eyes, 0.3 mg pegaptanib sodium in 20 eyes) was carried out in group II. The primary efficacy endpoint was the mean change from
baseline visual acuity at month 12.
Results: Mean follow-up was 14.2 ± 2.18 months in group I and 12.45 ± 2.82 months in group II. In group I there was a 2.88 logMAR
line decrease and 1.95 logMAR line increase in group II in vision between pretreatment and 12th month measurements (P < 0.05). Mean
PDT session was 2.00 in group I and the mean combined treatment session was 1.15 in group II in the 12th month.
Conclusion: Combination of IVTA and anti-VEGF with PDT is more effective and safer than PDT monotherapy in the treatment of
CNV secondary to AMD. Combination treatment decreases the frequency and number of treatment sessions for an improved visual
prognosis.
Key words: Age-related macular degeneration, bevacizumab, choroidal neovascularization, pegaptanib sodium, photodynamic therapy

1. Introduction
Age-related macular degeneration (AMD) is the most
common cause of central vision loss and legal blindness
in developed countries for persons over 65 years of age
(1,2). However, no complete therapy is proven for the
cure of exudative AMD. Argon laser photocoagulation
is commonly used in the treatment of extrafoveal
choroidal neovascularization (CNV) (2,3). New treatment
procedures such as photodynamic therapy (PDT) for
juxtafoveal and subfoveal CNV, intravitreal and periocular
steroid injections, and vascular endothelial growth factor
(VEGF) inhibitors that suppress angiogenesis have begun
to be used.
As a result of any hypoxia, VEGF is released from the
retinal and retinal pigment epithelium cells in very high
levels and then not only is neovascularization shown, but
also inflammation, vasodilatation, leakage from the vessels,
and hemorrhage might be seen in the same tissues (4,5).
Due to the multifactorial pathogenesis of CNV
development, AMD treatment should contain 3 main
factors, which are suppression of inflammation, regression

of present CNV, and prevention of CNV development
by inhibition of angiogenic stimulus (6). Due to the
multifactorial pathogenesis of CNV development in AMD
cases, the logic of treatment modalities should cover 3
main activities, which are suppression of inflammation
and edema, regression of the neovascular membrane,
and tamponade of the highly increased VEGF levels,
especially after PDT. However, there is no effective and
safe monotherapy that covers all 3 of these mechanisms.
Thus, new synergistic combination treatment protocols
that activate all of these pathways and require less
application have been commonly used (6,7). Combination
of PDT, intravitreal steroid, and vascular endothelial
growth factor inhibition (anti-VEGF) injections were used
together for this purpose. In these combination regimens,
an intravitreal steroid injection was used in order to
reduce retinal edema and hemorrhage as well as inhibit
VEGF production by suppressing inflammation (8,9).
Decreased retinal edema and hemorrhage should improve
the effectiveness of PDT. Anti-VEGF treatment is also
important for the prevention of new CNV development
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by inhibiting retinal and intravitreal basal VEGF as well
as intensive production of these growth factors after PDT
(6,10–12).
In this study, comparison of the effectiveness of
PDT monotherapy and PDT combined with intravitreal
triamcinolone acetonide (IVTA) and anti-VEGF in
neovascular AMD was the aim because treatment
modalities in wet AMD cases could not be agreed upon
and the finalization of treatment series is still controversial.
Therefore, we aimed to advance a different combination of
the known treatment modalities for a cheaper and easier
application series that has fewer intravitreal sessions and
better final visual acuity with some specific efficacy aimed
toward each elementary lesion of the disease.
2. Materials and methods
Eighty eyes of 80 patients diagnosed with CNV secondary
to AMD between January 2005 and July 2008 were
included in the study. The study was prospective. The
treatment protocol was approved by the local ethics
committee, and the study was conducted according to the
Declaration of Helsinki. Patients gave written informed
consent after a detailed discussion of the study procedures,
risks, and benefits before entering the study. For inclusion
in the study, the patient had to be 50 years or older, have
eyes with any type of active subfoveal CNV secondary to
neovascular AMD, and have a best-corrected visual acuity
(BCVA) of 20/400 or better (Snellen equivalent) assessed
with the use of the Early Treatment Diabetic Retinopathy
Study (ETDRS) charts. Exclusion criteria were glaucoma,
diabetic retinopathy, macular disorders other than AMD,
and previous treatment for CNV. Patients were randomly
divided into 2 groups in terms of treatment regimen. PDT
was carried out on 40 eyes in group I, while PDT combined
with 4 mg/0.1 cc IVTA (Kenacort-A® 40 mg, Bristol-Meyers
Squibb) and anti-VEGF (1.25 mg bevacizumab, Altuzan®,
Roche in 20 eyes; 0.3 mg pegaptanib sodium, Macugen®,
Pfizer in 20 eyes) was used in group II. At baseline, all
patients underwent an ophthalmological examination,
including BCVA measurement using the ETDRS logMAR
chart at 4 m, slit-lamp and fundus examination, and
intraocular pressure (IOP) measurement by Goldman
applanation tonometry. Optical coherence tomography
(OCT) was performed to assess retinal thickness.
Baseline 1-mm central retinal thickness was measured
by OCT (Stratus OCT with Stratus 4.0 software, Carl
Zeiss Meditec AG) using 6-diagonal fast scans. Standard
fluorescein angiography (FA) using the Heidelberg Retina
Angiograph II (Heidelberg Engineering) was performed
on all patients before treatment. Standard parameters were
used for PDT (Carl Zeiss Meditec AG) with verteporfin
(Visudyne®, Novartis) according to TAP and VIP trial
recommendations (13,14). On every visit, both ophthalmic
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examination and OCT were performed; FA was performed
within 3-month intervals.
Patients were scheduled for follow-up visits at 1-month
intervals and underwent identical examination procedures,
including BCVA measurement, IOP documentation,
slit-lamp and dilated fundus examination, and OCT
measurement. FA was performed every 3 months or
earlier if OCT showed significant edema. Retreatment was
performed if one of the following changes was observed
between visits: a loss of 5 letters in conjunction with fluid
in the macula as detected by OCT, an increase in OCT
central retinal thickness of at least 100 µm, new-onset
classic CNV, new macular hemorrhage, or persistent
macular fluid detected by OCT.
In group II, intravitreal injections were performed
under sterile conditions in the operating room. Four days
after the 4 mg IVTA injection, PDT was performed. AntiVEGF was injected 45 min after PDT. A topical antibiotic,
every 6 h for 1 week, was prescribed and patients were
instructed to return in case of ocular pain or redness or any
deterioration of vision. Patients were examined 1 day and
1 week after injection. Topical antiglaucoma medication
was prescribed if IOP was greater than 21 mmHg.
The primary outcome measure was the proportion of
eyes that maintained stable vision (<3 logMAR lines of
visual loss). Other outcome measures included changes
in BCVA logMAR, changes in the number of lines,
area of leakage from CNV, and the mean number of
treatments required during the 1-year study period. While
the change in the mean BCVA was evaluated, visual acuity
that was a loss of less than 3 logMAR lines was considered
as a success, but the loss of 3 logMAR lines and above was
considered as failure.
2.1. Statistical analysis
The data of the 2 groups were compared. Both parametric
and nonparametric tests were used according to the data,
including t-test, Mann–Whitney U test, chi-square test,
Fisher exact test, and Wilcoxon signed-rank for statistical
analysis.
3. Results
The study group comprised 80 patients, with 40 patients
for each group. Mean follow-up was 14.2 ± 2.18 months
(range: 12–19 months) in group I (PDT monotherapy)
and 12.45 ± 2.82 (range: 6–16) months in group II (PDT,
IVTA, and anti-VEGF combined treatment). All of the
patients completed 6 months of follow-up in both groups.
In group I, 40 patients completed 12 months of follow-up.
In group II, 5 patients were not able to complete 12 months
of follow-up. Three out of 5 patients died due to geriatric
problems and 2 missed their visits because of living outside
of the city during the follow-up period. There were no
statistical differences between the baseline demographics
of the groups (Table) (P ≤ 0.05).
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Table. Baseline demographics of the patients.
Group I
n = 40

Group II
n = 40

Male

14 (35%)

20 (50%)

Female

26 (65%)

20 (50%)

Mean age (years, mean ± SD)

71.0 ± 8.93

71.8 ± 8.32

Phakic

28 (70%)

31 (77.5%)

Pseudophakic

12 (30%)

9 (22.5%)

Mean follow-up time (months)

14.2 ± 2.18

12.45 ± 2.82

Predominantly classic

22 (55%)

25 (62.5%)

Occult

13 (32.5%)

11 (27.5%)

Minimally classic

5 (12.5%)

4 (10%)

Mean baseline CNV

3751 ± 1259

3846 ± 1351

0.95 ± 0.34

0.90 ± 0.43

Membrane type

Greatest linear dimension (µm)
Mean baseline
BCVA (logMAR)

1.40
1.20
1.00
0.80
0.60
0.40
0.20
0.00

Group II

Group I
0.95

0.97

0,90

0.81

baseline

month 1

1.06

1.11

0.74

0.75

month 3

month 6

II is shown in Figure 2. Although the success rate in group
II was higher than that of group I in all of the months, it
was not statistically significant in any of the months (P ≥
0.05). The proportion of the patients for whom the mean
BCVA increased by at least 3 logMAR lines in group I
and group II is shown in Figure 3. The difference between
groups was statistically significant at 6 and 12 months
(P ≤ 0.05). During the follow-up period, when the mean
BCVA at the rate of loss of 6 logMAR lines and above
was compared between the groups, the difference was not
significant (P ≥ 0.05).
The patients were categorized into 4 groups according
to the findings of FA at 3, 6, and 12 months as no leakage,
minimal leakage (less than 50% of baseline leakage),
100
80

1.27
(%)

logMAR BCVA

Change in BCVA from baseline to the time of the last
follow-up visit in groups I and II patients are shown in
Figure 1. When the mean BCVA was measured in group I
patients, it was seen that when the follow-up period lasted
longer there was a decrease in the mean BCVA. Among
the patients in group II, the mean BCVA was significantly
improved at the first month and the improvement was
maintained throughout the 12 months of follow-up. Of the
patients who were treated with combined therapy in group
II, there were, on average, 1.50 and 1.95 logMAR lines of
gain in vision at 6 and 12 months, respectively, as compared
with an average decrease of 1.57 and 2.88 logMAR lines in
group I patients (PDT monotherapy group) at 6 and 12
months, respectively (P ≤ 0.05).
The proportion of patients whose treatment was
successful (<3 logMAR lines of visual loss) in group I and

0.71

month 12

Figure 1. Change in mean BCVA from baseline to the time of the
last follow-up visit.

Group I
75

87.5

Group II
90
70

88.6

87.5
67.5

60

56.3

40
20
0

month 1

month 3

month 6

month 12

Figure 2. The proportion of the patients whose treatment was
successful.
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40.0

Group 1

(%)

20.0

32.5

Group 2

30.0

20.0

22.5
17.5

10.0
0.0

31.4

30

7.5

month 1

month 3

5

month 6

month 12

Figure 3. The proportion of the patients for whom the mean
BCVA increased by at least 3 logMAR lines.

moderate leakage (more than 50% of baseline leakage),
and increased leakage (equal to or greater than baseline
leakage). According to FA leakage, no leakage or minimal
leakage was considered as treatment success and moderate
leakage was considered as treatment failure. The group
that was found to be unsuccessful was treated again.
Success rate in FA in groups I and II is shown in Figure 4.
The difference between groups was statistically significant
in all months (P ≤ 0.05). Mean central foveal thickness
(CFT) of the patients in groups I and II is shown in Figure
5. The decrease in the mean CFT after treatment compared
120

Failure

(%)

100
80

Success
8

20

22.5

46.9

47.5

52.5

60
40
20
0

53.1

52.5

47.5

group I

92

80

77.5

group II group I group II group I group II
month 3 month 6 month 12

Figure 4. Success rate in FA.
500
CFT (µm)

400
300
200
100
0
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408

405

395

368

309

279

270
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392
Group I
Group II
baseline

month 1

month 3

month 6

month 12

Figure 5. Change in mean central foveal thickness (CFT) from
baseline to the time of the last follow-up visit.
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with baseline was statistically significant only at 12 months
in group I (P ≤ 0.05), but was statistically different at all
months in group II (P ≤ 0.05).
The patients for whom PDT monotherapy was
performed in group I were followed for an average of 14.2
± 2.18 (range: 12–19) months. These patients attended
a mean of 2 sessions of PDT. PDT was performed at 1
session (35%) in 14 eyes, 2 sessions (40%) in 16 eyes, 3
sessions (17.5%) in 7 eyes, 4 sessions (5%) in 2 eyes, and
5 sessions (2.5%) in 1 eye. The patients who were treated
with combined therapy in group II were followed for
an average of 12.45 ± 2.82 (range: 6–16) months. These
patients attended an average of 1.15 sessions of combined
treatment. Thirty-four eyes (85%) were treated with only
a single combination therapy and 6 eyes (15%) with
activation of CNV were treated with combined therapy
a second time. Thirteen eyes that had been treated with
a single combination therapy were injected intravitreally
with anti-VEGF or intravitreal anti-VEGF + IVTA (antiVEGF into 4 eyes once, anti-VEGF 2 times into 4 eyes,
and anti-VEGF + IVTA into 5 eyes) due to decreased
visual acuity and increased intraretinal or subretinal fluid
accumulation. There was no need for additional PDT or
intravitreal injections for 60% of the patients after the
initial combined treatment.
Generally, the treatments were well tolerated in both
groups. Infusion-related back pain was noted in 2 out of
40 (5%) patients and subretinal hemorrhage developed
2 weeks after the treatment in 1 (2.5%) patient in group
I. In group II, infusion-related back pain was noted in 3
out of 40 (7.5%) patients, cataracts progressed in 5 out of
31 (16.1%) phakic patients, and a transient IOP increase
was observed in 4 (10%) patients, which was controlled
by topical monotherapy during the follow-up period. One
(2.5%) patient with high IOP and cataract progression
underwent combined glaucoma and cataract surgery 6
months after the treatment. Complications attributable to
the injection procedure, such as pseudoendophthalmitis,
retinal detachment, retinal tears, or vitreous hemorrhage,
were not observed.
4. Discussion
In this study, we applied combined treatment regimens
including IVTA and anti-VEGF (bevacizumab or
pegaptanib) injections with PDT. IVTA injection was
performed initially, and PDT and intravitreal anti-VEGF
injections occurred after 4 days in the combination
regimen. IVTA helped to regress the macular inflammation
so that the effects of inflammatory mediators and especially
macular edema were inhibited. PDT was performed due
to occlusion of neovascularization approximately 4 or 5
days later than IVTA. The inflammatory mediators and
VEGF tend to rise after PDT. Inflammation was inhibited
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by the ongoing effect of triamcinolone (TA) and VEGF
proliferation was suppressed by the anti-VEGF agent
that was applied within 45 min after PDT. Suppression of
inflammation and VEGF production, vaso-occlusion in
present CNV, and limitation of atrophic scar development
in late stages were expected from this combination
treatment regimen. This combination treatment can
also be used in the treatment of various retinal vascular
diseases. Toklu et al. (15) reported that all 6 patients with
chronic central serous chorioretinopathy showed complete
resolution of the exudative macular detachments and
gained visual acuity for more than 6 months with the usage
of combination therapy with a half-dose of verteporfin
PDT and intravitreal ranibizumab injection.
PDT is a therapy procedure that decreases the
risk of severe vision loss by 50% compared to the natural
course of the disease (16). On average, 3 lines of loss in
visual acuity were revealed with the mean of 3.4 treatment
sessions within the first year in TAP and VIP studies (16).
Transient thrombosis at the retina and choriocapillaris may
be seen after treatment and PDT with verteporfin has a high
selectivity to neovascular membranes vessels (16). Early
inflammatory response and stimulated VEGF expression
secondary to transient thrombosis at choriocapillaris after
PDT may also cause frequent recurrences of AMD (17,18).
However, stabilization in visual acuity was seen in 67.5%
of the patients who received PDT monotherapy at month
6 of our study, while vision loss progressed afterwards.
At the end of the 12 months of follow-up, stabilization in
visual acuity was determined in 56.3% of the patients with
a mean of 2 treatment sessions.
The efficacy of ranibizumab monotherapy and
treatment with a PDT-ranibizumab combination were
compared in the FOCUS study (19). In the first year of the
study, 3 or fewer lines of loss in vision were found at 91% in
the combination group and 68% in the PDT monotherapy
group. Moreover, 3 or more lines of gain in vision were
detected at 24% in the combination group and 5.5% in the
PDT monotherapy group. On average, 1 line of gain in
vision was seen in the combination group while 1.6 average
lines of loss in visual acuity were revealed in the PDT
monotherapy group within the first year of the study (19).
Chan et al. (20) compared the efficacy of triamcinolone
combination with PDT and PDT monotherapy. On
average, 3.5 and 0.7 logMAR lines of loss in vision were
found in the PDT monotherapy and combination groups,
respectively, at the 12th month of the study. In addition,
fewer than 3 lines of loss in vision were revealed at 70.8%
and 33.3% in the combination and PDT monotherapy
groups, respectively (20). The MONT BLANC study
(21) and the DENALI study (22) compared the results of
combination therapy of verteporfin PDT and intravitreal
ranibizumab versus ranibizumab monotherapy in patients

with AMD-related subfoveal CNV. The mean BCVA gains
in the combination therapy and monotherapy group were
2.5 and 4.4 letters in the MONT BLANC study (21) and 5.3
and 8.1 letters in the DENALI study (22), respectively. The
mean number of ranibizumab retreatments after month 2
in the combination therapy and monotherapy group was
1.9–2.2 in the MONT BLANC study (21) and 5.1–10.5 in
the DENALI study (22). Monotherapy and combination
therapy both had visual gains at month 12, but in the MONT
BLANC study (21), it was not shown that there was any
benefit of reduced retreatment numbers from intravitreal
ranibizumab injection over 12 months. In our study, the
frequency and efficacy of PDT monotherapy and IVTA
and anti-VEGF (bevacizumab or pegaptanib) injections
combined with PDT were reviewed for the treatment of
CNV secondary to AMD. Stabilization in vision (less than
3 lines of loss) was achieved at 56.3% and 88.6% of the
patients in the monotherapy group and the combination
group at the 12th month of the study, respectively (P ≥
0.05). The success rate (less than 3 lines of loss) at the 12th
month of our study mimics the results of the FOCUS study
(18). However, an average of 2.88 logMAR lines of loss in
vision were found in the PDT monotherapy group at the
12th month. In our study, we have reported 1.95 logMAR
of visual gain in the combination group at the 12th month,
which is similar to the findings of the MONT BLANC
(21) and DENALI (22) studies. Additionally, 3 or more
lines of gain in vision were found at 5% and 31.4% in the
PDT monotherapy and combination groups at 12 months,
respectively.
Mean visual gain scores and 3 or more lines of gain
in vision in our study were found to be higher than the
reported values of FOCUS (18) and the study of Chan
et al. (20). Ninety-one percent of the patients in the
PDT group required additional sessions of treatment in
the FOCUS (19) trial, while on average 4 sessions were
performed in approximately 30% of the cases. Only
27.5% of the patients in the combination treatment group
required a second application. Mean treatment sessions
of Chan et al. (20) were 1.50 and 1.96 in the IVTA-PDT
combination treatment group and the PDT monotherapy
group, respectively. When the mean treatment sessions of
our study were compared with these 2 studies mentioned
above, it was seen that fewer applications were needed
in the combination therapy group of our study. A mean
of 2 and 1.15 treatment sessions were required in the
PDT monotherapy and combination therapy groups,
respectively, in our study. Additional full combination
therapy was performed in 6 (15%) eyes of the combination
therapy subgroup that had CNV activation. Additional
bevacizumab/pegaptanib injections or IVTA combined
with bevacizumab/pegaptanib injections were performed
on 13 eyes (32.5%) because of vision loss and intraretinal/
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subretinal fluid accumulation. When intravitreal injections
were taken into account, the mean of treatment sessions in
the combination subgroup of our study was 1.40. There was
no need for additional application with PDT or intravitreal
injection in 60% of our study population.
The most appropriate treatment combination is still
obvious. PDT and IVTA, PDT and anti-VEGF agent, or
triple combinations may be preferred (20,23,24). There is
also disagreement about the timing of the therapy. While
Chan et al. (20) preferred to apply corticosteroids 5 min
after PDT, Augustin et al. (6) and Ahmedieh et al. (25)
applied dexamethasone and bevacizumab intravitreally
16 h and 48 h after PDT, respectively. Ranibizumab was
intravitreally injected 1 week after PDT in the PIER study
(16). Dallha et al. (24) applied intravitreal bevacizumab
2 weeks after PDT. We applied IVTA and anti-VEGF
(bevacizumab or pegaptanib) injections with PDT. IVTA
injection was performed initially with PDT and intravitreal
anti-VEGF injection following in our combination
regimen. Augustin et al. (6) applied 800 µg dexamethasone
and 1.50 mg bevacizumab with PDT to 104 patients with
CNV secondary to AMD. The mean diameter of CNV
was reported as 2650 µm in this study. After 40 weeks of
follow-up, fewer than 3 lines of loss in vision were achieved
in 97% of the study population. Additionally, 3 lines or
more of gain in vision were found at 39.4% and a mean of
1.80 logMAR lines of gain in visual acuity was reported.
They applied additional combination therapy in 5 cases.
Intravitreal reinjection of bevacizumab was performed in
18 cases (17.3%). In our study, we applied TA and antiVEGF intravitreally with PDT. Our success rates were
lower than those of Augustin et al. (6). However, the mean
lesion diameters in their study were smaller than the mean
lesion diameter of our study, which was detected as 3846

µm. The mean follow-up time of our study was longer. The
treatment frequency of our study was found to be higher
than that of the trial of Augustin et al. (6).
Complications such as glaucoma, cataract, uveitis,
retinal detachment, and endophthalmitis may progress
due to intravitreal injections. Glaucoma and cataract
progression secondary to IVTA application were
particularly reported in many series (6,20,24,25). Augustin
et al. (26) reported glaucoma in 46 patients (25%) after
treatment with 25 mg IVTA combined with PDT and
antiglaucomatous medication was started in these cases.
They also performed surgery on 2 patients (1.08%) because
of refractory glaucoma that could not be controlled by
medication. Cataract progression was detected in 48.7%
of the phakic cases. Chan et al. (20) reported glaucoma in
33.3% and cataract in 26.3% of the patients who received
4 mg IVTA with PDT. When our study was compared to
these series, progression of cataract and glaucoma were
less frequent in our patients. Glaucoma was detected in
12.5% and cataract progression was detected in 16.1% of
the cases. Cataract combined with glaucoma surgery was
performed in a case that was refractory to medication.
Progression of cataract and glaucoma was not reported in
the study of Augustin et al. (6), which tested the efficacy
of 800 µm dexamethasone and 1.25 mg bevacizumab
combined with PDT, and so they recommended the
application of dexamethasone instead of TA.
In light of the results of this study, safe and effective
stabilization or improvement in vision was achieved by
IVTA and anti-VEGF injections combined with PDT
in patients with CNV secondary to AMD. Frequency of
treatment was also decreased in combination regimens.
Less frequent application is both cost-effective and more
satisfactory for the patients with AMD.
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